Alzheimer's disease (AD) is a complex neurodegenerative disorder characterized by progressive cognitive decline and multifaceted pathogenic mechanisms (including amyloid-β [Aβ] plaques, tau neurofibrillary tangles, synaptic dysfunction, and neuroinflammation). Importantly, no effective disease-modifying treatment is currently available for AD. Emerging evidence implicates dysregulated mammalian target of rapamycin (mTOR) signaling as a key contributor to AD pathogenesis. This review analyzes how aberrant mTOR signaling influences major aspects of AD pathology, including Aβ production and clearance, tau protein hyperphosphorylation, autophagy dysfunction, synaptic plasticity impairments, neuroinflammation, and oxidative stress. Notably, hyperactivated mTOR accelerates AD progression through multiple mechanisms. It promotes Aβ accumulation and tau pathology, suppresses autophagic clearance of toxic aggregates, and disrupts neuronal homeostasis, thereby exacerbating cognitive decline. Consequently, mTOR has gained attention as a therapeutic target. This review evaluates the therapeutic potential of various mTOR-targeted interventions, such as the mTORC1 inhibitor rapamycin and its analogues (rapalogs), second-generation ATP-competitive mTOR inhibitors, and certain natural compounds and traditional Chinese medicine approaches. These strategies have demonstrated promise in mitigating AD-related pathology by enhancing autophagy, reducing Aβ/tau burden, and preserving synaptic and cognitive function in preclinical studies. However, the clinical translation of mTOR-targeted therapies faces key challenges, including poor blood–brain barrier penetration of many mTOR inhibitors, potential systemic side effects, and limited clinical validation to date. Further research is needed to optimize brain delivery, dosing regimens, and target specificity to fully realize the therapeutic potential of mTOR modulation in AD.
ZhangJZhangYWangJ, et al.Recent advances in Alzheimer’s disease: mechanisms, clinical trials and new drug development strategies. Signal Transduct Target Ther2024; 9: 211.
QuerfurthHWLaFerlaFM. Alzheimer’s disease. N Engl J Med2010; 362: 329–344.
4.
CanoATurowskiPEttchetoM, et al.Nanomedicine-based technologies and novel biomarkers for the diagnosis and treatment of Alzheimer’s disease: from current to future challenges. J Nanobiotechnol2021; 19: 122.
5.
LiuJJLongYFXuP, et al.Pathogenesis of miR-155 on nonmodifiable and modifiable risk factors in Alzheimer’s disease. Alzheimers Res Ther2023; 15: 122.
6.
BandakindaMMishraA. Insights into role of microRNA in Alzheimer’s disease: from contemporary research to bedside perspective. Int J Biol Macromol2023; 253: 126561.
7.
GiacobiniECuelloACFisherA. Reimagining cholinergic therapy for Alzheimer’s disease. Brain2022; 145: 2250–2275.
8.
ZhangFZhongRJChengC, et al.New therapeutics beyond amyloid-β and tau for the treatment of Alzheimer’s disease. Acta Pharmacol Sin2021; 42: 1382–1389.
9.
LiuGYSabatiniDM. mTOR at the nexus of nutrition, growth, ageing and disease. Nat Rev Mol Cell Biol2020; 21: 183–203.
10.
SaxtonRASabatiniDM. mTOR signaling in growth, metabolism, and disease. Cell2017; 168: 960–976.
11.
XuTSunDChenY, et al.Targeting mTOR for fighting diseases: a revisited review of mTOR inhibitors. Eur J Med Chem2020; 199: 112391.
12.
GaoJYaoMChangD, et al.mTOR (mammalian target of rapamycin): hitting the bull’s eye for enhancing neurogenesis after cerebral ischemia?Stroke2023; 54: 279–285.
13.
QuerfurthHLeeHK. Mammalian/mechanistic target of rapamycin (mTOR) complexes in neurodegeneration. Mol Neurodegener2021; 16: 44.
14.
PerluigiMDi DomenicoFButterfieldDA. mTOR signaling in aging and neurodegeneration: at the crossroad between metabolism dysfunction and impairment of autophagy. Neurobiol Dis2015; 84: 39–49.
15.
KoehlMLadevèzeECataniaC, et al.Inhibition of mTOR signaling by genetic removal of p70 S6 kinase 1 increases anxiety-like behavior in mice. Transl Psychiatry2021; 11: 165.
16.
PerluigiMDi DomenicoFBaroneE, et al.mTOR in Alzheimer disease and its earlier stages: links to oxidative damage in the progression of this dementing disorder. Free Radic Biol Med2021; 169: 382–396.
17.
CironeM. Cancer cells dysregulate PI3K/AKT/mTOR pathway activation to ensure their survival and proliferation: mimicking them is a smart strategy of gammaherpesviruses. Crit Rev Biochem Mol Biol2021; 56: 500–509.
18.
PanwarVSinghABhattM, et al.Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease. Signal Transduct Target Ther2023; 8: 375.
19.
WangYVandewalleNDe VeirmanK, et al.Targeting mTOR signaling pathways in multiple myeloma: biology and implication for therapy. Cell Commun Signal2024; 22: 320.
20.
KaralisVCaval-HolmeFBateupHS. Raptor downregulation rescues neuronal phenotypes in mouse models of tuberous sclerosis complex. Nat Commun2022; 13: 4665.
21.
SunYWangHQuT, et al.mTORC2: a multifaceted regulator of autophagy. Cell Commun Signal2023; 21: 4.
22.
WangJHuangYWangZ, et al.The mTOR signaling pathway: key regulator and therapeutic target for heart disease. Biomedicines2025; 13: 397.
23.
ConciatoriFCiuffredaLBazzichettoC, et al.mTOR cross-talk in cancer and potential for combination therapy. Cancers (Basel)2018; 10: 23.
24.
FuWHallMN. Regulation of mTORC2 signaling. Genes (Basel)2020; 11: 1045.
25.
DuanQYangWZhuX, et al.Deptor protects against myocardial ischemia-reperfusion injury by regulating the mTOR signaling and autophagy. Cell Death Discov2024; 10: 508.
26.
XiongXChenXShaoS, et al.DEPTOR Suppresses lymphomagenesis by promoting EGFR degradation via HUWE1 E3 ligase. Cell Death Differ2025; 32: 1820–1832.
27.
SuharaTBabaYShimadaBK, et al.The mTOR signaling pathway in myocardial dysfunction in type 2 diabetes mellitus. Curr Diab Rep2017; 17: 38.
WangGChenLQinS, et al.Mechanistic target of rapamycin complex 1: from a nutrient sensor to a key regulator of metabolism and health. Adv Nutr2022; 13: 1882–1900.
32.
LinSWangLJiaY, et al.Lipin-1 deficiency deteriorates defect of fatty acid β-oxidation and lipid-related kidney damage in diabetic kidney disease. Transl Res2024; 266: 1–15.
33.
WangJYChenMPJiangJX, et al.Lipin1-dependent transcriptional inactivation of SREBPs contributes to selinexor sensitivity in multiple myeloma. Acta Pharmacol Sin2025; 46: 2496–2508.
34.
SuFKoeberleA. Regulation and targeting of SREBP-1 in hepatocellular carcinoma. Cancer Metastasis Rev2024; 43: 673–708.
35.
LiuBLiuF. Feedback regulation of mTORC1 by Grb10 in metabolism and beyond. Cell Cycle2014; 13: 2643–2644.
36.
MelickCHJewellJL. Regulation of mTORC1 by upstream stimuli. Genes (Basel)2020; 11: 989.
37.
D’AgostinoSDaviesCPowersMV, et al.Advances in understanding and targeting eIF4E activity. Biochem Soc Trans2025; 53: 801–822.
38.
HochstoegerTPapasaikasPPiskadloE, et al.Distinct roles of LARP1 and 4EBP1/2 in regulating translation and stability of 5′TOP mRNAs. Sci Adv2024; 10: eadi7830.
39.
RoiukMNeffMTelemanAA. eIF4E-independent translation is largely eIF3d-dependent. Nat Commun2024; 15: 6692.
40.
SabaJAHuangZScholeKL, et al.LARP1 Binds ribosomes and TOP mRNAs in repressed complexes. EMBO J2024; 43: 6555–6572.
41.
YongJKimHLeeE, et al.Regulation of transcriptome plasticity by mTOR signaling pathway. Exp Mol Med2025; 57: 1623–1630.
42.
ChenLGaoTZhouP, et al.Recent advances of vacuolar protein-sorting 34 inhibitors targeting autophagy. Bioorg Chem2024; 143: 107039.
43.
JoshiJNLernerADScalloF, et al.mTORC1 activity oscillates throughout the cell cycle, promoting mitotic entry and differentially influencing autophagy induction. Cell Rep2024; 43: 114543.
44.
KimDH. Contrasting views on the role of AMPK in autophagy. Bioessays2024; 46: e2300211.
45.
SmilesWJOvensAJKempBE, et al.New developments in AMPK and mTORC1 cross-talk. Essays Biochem2024; 68: 321–336.
46.
ChenMHurleyJH. The human autophagy-initiating complexes ULK1C and PI3KC3-C1. J Biol Chem2025; 301: 110391.
47.
CookASIChenMNguyenTN, et al.Structural pathway for PI3-kinase regulation by VPS15 in autophagy. Science2025; 388: eadl3787.
48.
HanXGohKYLeeWX, et al.The importance of mTORC1-autophagy axis for skeletal muscle diseases. Int J Mol Sci2023; 24: 10297.
49.
XieYLeiXZhaoG, et al.mTOR in programmed cell death and its therapeutic implications. Cytokine Growth Factor Rev2023; 71–72: 66–81.
50.
ChenHGongSZhangH, et al.From the regulatory mechanism of TFEB to its therapeutic implications. Cell Death Discov2024; 10: 84.
51.
TaklaMKeshriSRubinszteinDC. The post-translational regulation of transcription factor EB (TFEB) in health and disease. EMBO Rep2023; 24: e57574.
52.
ZwakenbergSWestlandDvan EsRM, et al.mTORC1 restricts TFE3 activity by auto-regulating its presence on lysosomes. Mol Cell2024; 84: 4368–4384.e4366.
53.
RagupathiAKimCJacintoE. The mTORC2 signaling network: targets and cross-talks. Biochem J2024; 481: 45–91.
54.
MarafieSKAl-MullaFAbubakerJ. mTOR: its critical role in metabolic diseases, cancer, and the aging process. Int J Mol Sci2024; 25: 6141.
55.
YangFChenCChenR, et al.Unraveling the potential of SGK1 in osteoporosis: from molecular mechanisms to therapeutic targets. Biomolecules2025; 15: 686.
56.
ParkJSGabelAMKassirP, et al.N-myc downstream regulated gene 1 (ndrg1) functions as a molecular switch for cellular adaptation to hypoxia. eLife2022; 11: e74031.
57.
SaponaroCGammaldiNCavalloV, et al.Insight into the regulation of NDRG1 expression. Int J Mol Sci2025; 26: 3582.
58.
Abo-ElenienWIBadawySGAboueleninO, et al.Role of SGK1 in cancer: a bibliometric analysis from 2013 to 2023—review article. Egypt J Med Hum Genet2024; 25: 142.
59.
SzwedAKimEJacintoE. Regulation and metabolic functions of mTORC1 and mTORC2. Physiol Rev2021; 101: 1371–1426.
60.
IkenoueTInokiKYangQ, et al.Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling. EMBO J2008; 27: 1919–1931.
61.
AnPXuWLuoJ, et al.Expanding TOR complex 2 signaling: emerging regulators and new connections. Front Cell Dev Biol2021; 9: 713806.
62.
Morrison JolyMWilliamsMMHicksDJ, et al.Two distinct mTORC2-dependent pathways converge on Rac1 to drive breast cancer metastasis. Breast Cancer Res2017; 19: 74.
63.
ZhaoYSchoepsBYaoD, et al.mTORC1 and mTORC2 converge on the Arp2/3 complex to promote Kras(G12D)-induced acinar-to-ductal metaplasia and early pancreatic carcinogenesis. Gastroenterology2021; 160: 1755–1770.e1717.
64.
FilipponeAEspositoEManninoD, et al.The contribution of altered neuronal autophagy to neurodegeneration. Pharmacol Ther2022; 238: 108178.
65.
OndaroJHernandez-EguiazuHGarciandia-ArcelusM, et al.Defects of nutrient signaling and autophagy in neurodegeneration. Front Cell Dev Biol2022; 10: 836196.
66.
CaiZChenGHeW, et al.Activation of mTOR: a culprit of Alzheimer’s disease?Neuropsychiatr Dis Treat2015; 11: 1015–1030.
67.
SubramanianATamilanbanTAlsayariA, et al.Trilateral association of autophagy, mTOR and Alzheimer’s disease: potential pathway in the development for Alzheimer’s disease therapy. Front Pharmacol2022; 13: 1094351.
68.
Di DomenicoFTramutolaAFoppoliC, et al.mTOR in Down syndrome: role in Aβ and tau neuropathology and transition to Alzheimer disease-like dementia. Free Radic Biol Med2018; 114: 94–101.
69.
ChengJNorthBJZhangT, et al.The emerging roles of protein homeostasis-governing pathways in Alzheimer’s disease. Aging Cell2018; 17: e12801.
70.
HaqueMAPoullikkasTAl-Amin KaisarFM, et al.PHLPP1 Depletion promotes tumorigenesis and stemness in triple-negative breast cancer cells through AKT signaling. Med Oncol2025; 42: 80.
71.
LimantoroJde LiyisBGSutedjaJC. Akt signaling pathway: a potential therapy for Alzheimer’s disease through glycogen synthase kinase 3 beta inhibition. Egypt J Neurol Psychiatr Neurosurg2023; 59: 147.
72.
Sanz-CastilloBHurtadoBVara-CiruelosD, et al.The MASTL/PP2A cell cycle kinase-phosphatase module restrains PI3K–Akt activity in an mTORC1-dependent manner. EMBO J2023; 42: e110833.
73.
DuMRGaoQYLiuCL, et al.Exploring the pharmacological potential of metformin for neurodegenerative diseases. Front Aging Neurosci2022; 14: 838173.
74.
HassanMYasirMShahzadiS, et al.Molecular role of protein phosphatases in Alzheimer’s and other neurodegenerative diseases. Biomedicines2024; 12: 1097.
75.
SontagJMSchuhmacherDTaleskiG, et al.A new paradigm for regulation of protein phosphatase 2A function via Src and Fyn kinase-mediated tyrosine phosphorylation. J Biol Chem2022; 298: 102248.
76.
TangZBereczkiEZhangH, et al.Mammalian target of rapamycin (mTor) mediates tau protein dyshomeostasis: implication for Alzheimer disease. J Biol Chem2013; 288: 15556–15570.
77.
XiePLZhengMYHanR, et al.Pharmacological mTOR inhibitors in ameliorating Alzheimer’s disease: current review and perspectives. Front Pharmacol2024; 15: 1366061.
78.
RomanyukNSintakovaKArzhanovI, et al.mTOR pathway inhibition alters proliferation as well as differentiation of neural stem cells. Front Cell Neurosci2024; 18: 1298182.
79.
SwitonKKotulskaKJanusz-KaminskaA, et al.Molecular neurobiology of mTOR. Neuroscience2017; 341: 112–153.
80.
XuTLiuJLiXR, et al.The mTOR/NF-κB pathway mediates neuroinflammation and synaptic plasticity in diabetic encephalopathy. Mol Neurobiol2021; 58: 3848–3862.
81.
ChadhaRAlganemKMcCullumsmithRE, et al.mTOR kinase activity disrupts a phosphorylation signaling network in schizophrenia brain. Mol Psychiatry2021; 26: 6868–6879.
82.
HuangCWenCYangM, et al.Astaxanthin improved the cognitive deficits in APP/PS1 transgenic mice via selective activation of mTOR. J Neuroimmune Pharmacol2021; 16: 609–619.
83.
ZhouSLiuJSunY, et al.Dietary choline metabolite TMAO impairs cognitive function and induces hippocampal synaptic plasticity declining through the mTOR/p70S6K/4EBP1 pathway. Food Funct2023; 14: 2881–2895.
84.
FrancoisAVeriteJBilanAR, et al.The mTOR signaling pathway in neurodegenerative diseases. In: MaieseK (ed) Molecules to medicine with mTOR. Boston: Academic Press, 2016, pp.85–104.
85.
RapakaDBitraVRChallaSR, et al.mTOR signaling as a molecular target for the alleviation of Alzheimer’s disease pathogenesis. Neurochem Int2022; 155: 105311.
86.
GoulCPeruzzoRZoncuR. The molecular basis of nutrient sensing and signalling by mTORC1 in metabolism regulation and disease. Nat Rev Mol Cell Biol2023; 24: 857–875.
87.
HenryFEHockeimerWChenA, et al.Mechanistic target of rapamycin is necessary for changes in dendritic spine morphology associated with long-term potentiation. Mol Brain2017; 10: 50.
88.
HenryFEWangXSerranoD, et al.A unique homeostatic signaling pathway links synaptic inactivity to postsynaptic mTORC1. J Neurosci2018; 38: 2207–2225.
89.
ZhangSLinXHouQ, et al.Regulation of mTORC1 by amino acids in mammalian cells: a general picture of recent advances. Anim Nutr2021; 7: 1009–1023.
90.
StachoMManahan-VaughanD. The intriguing contribution of hippocampal long-term depression to spatial learning and long-term memory. Front Behav Neurosci2022; 16: 806356.
91.
TsokasPBlitzerRD. mTOR and the regulation of translational capacity in late forms of synaptic plasticity. In: SajikumarS (ed) Synaptic tagging and capture: from synapses to behavior. New York, NY: Springer, 2015, pp.99–132.
92.
WangMJinBJoJ. Acute restraint stress induces long-lasting synaptic enhancement by inhibiting AMPK activation in AD model mice. CNS Neurosci Ther2025; 31: e70335.
93.
KhamsingDLebrunSFangetI, et al.A role for BDNF- and NMDAR-induced lysosomal recruitment of mTORC1 in the regulation of neuronal mTORC1 activity. Mol Brain2021; 14: 112.
94.
GlavianoAFooASCLamHY, et al.PI3K/AKT/mTOR Signaling transduction pathway and targeted therapies in cancer. Mol Cancer2023; 22: 138.
95.
CheonJKwonSKimM. Exerkines mitigating Alzheimer’s disease progression by regulating inflammation: focusing on macrophage/microglial NLRP3 inflammasome pathway. Alzheimers Dement2025; 21: e14432.
96.
Di BenedettoGBurgalettoCBellancaCM, et al.Role of microglia and astrocytes in Alzheimer’s disease: from neuroinflammation to Ca2+homeostasis dysregulation. Cells2022; 11: 2728.
97.
GuoJZhuYZhiJ, et al.Antioxidants in anti-Alzheimer’s disease drug discovery. Ageing Res Rev2025; 107: 102707.
98.
Jarne-FerrerJPallàsMGriñán-FerréC, et al.Investigating the synergistic neuroprotective effects of plant-derived antioxidants and the psychedelic N,N-dimethyltryptamine in Alzheimer’s disease therapy. Cells2025; 14: 934.
99.
KshirsagarNPatilASuryawanshiM. Bioactive compound nanoparticles for Alzheimer’s disease. Inflammopharmacology2025; 33: 2963–2976.
100.
LiuTKongXQiaoJ, et al.Decoding Parkinson’s disease: the interplay of cell death pathways, oxidative stress, and therapeutic innovations. Redox Biol2025; 85: 103787.
101.
ArdizzoneAScuderiSACasiliG, et al.PI3K/mTOR Signaling pathway dual inhibition for the management of neuroinflammation: novel insights from in vitro models. Biomolecules2025; 15: 677.
102.
KoYSRyuYKHanS, et al.Hearing modulation affects Alzheimer’s disease progression linked to brain inflammation: a study in mouse models. Mol Med2024; 30: 276.
103.
KhonsariFHeydariMSharifzadehM, et al.Transferrin-decorated nanostructured lipid carriers are a promising delivery system for rapamycin in Alzheimer’s disease: an in vivo study. Biomater Adv2022; 137: 212827.
104.
ZhangWYWeiQQZhangT, et al.Microglial AKAP8L: a key mediator in diabetes-associated cognitive impairment via autophagy inhibition and neuroinflammation triggering. J Neuroinflammation2024; 21: 177.
105.
EstfanousSDailyKPEltobgyM, et al.Elevated expression of miR-17 in microglia of Alzheimer’s disease patients abrogates autophagy-mediated amyloid-β degradation. Front Immunol2021; 12: 705581.
106.
HeinZMVishnumukkalaTKarikalanB, et al.Autophagy and Alzheimer’s disease: mechanisms and impact beyond the brain. Cells2025; 14: 911.
107.
ZengLZhaoKLiuJ, et al.Long noncoding RNA GAS5 acts as a competitive endogenous RNA to regulate GSK-3β and PTEN expression by sponging miR-23b-3p in Alzheimer’s disease. Neural Regen Res2026; 21: 392–405.
108.
CuiJZhaoC. Autophagy and apoptosis in Alzheimer’s disease-associated neurons. Discov Neurosci2025; 20: 11.
109.
KumariSDhapolaRReddyDH. Apoptosis in Alzheimer’s disease: insight into the signaling pathways and therapeutic avenues. Apoptosis2023; 28: 943–957.
110.
García-JuanMOrdóñez-GutiérrezLWandosellF. Clearance of β-amyloid mediated by autophagy is enhanced by MTORC1 inhibition but not AMPK activation in APP/PSEN1 astrocytes. Glia2024; 72: 588–606.
111.
BalusuSDe StrooperB. The necroptosis cell death pathway drives neurodegeneration in Alzheimer’s disease. Acta Neuropathol2024; 147: 96.
112.
WohlfertAJPharesJGranholmAC. The mTOR pathway: a common link between Alzheimer’s disease and Down syndrome. J Clin Med2024; 13: 6183.
113.
XingDZhangWCuiW, et al.SIRT4 Promotes neuronal apoptosis in models of Alzheimer’s disease via the STAT2–SIRT4–mTOR pathway. Am J Physiol Cell Physiol2024; 326: C1697–C1709.
114.
LiuZJiaJ. Omaveloxolone ameliorates cognitive deficits by inhibiting apoptosis and neuroinflammation in APP/PS1 mice. Mol Neurobiol2025; 62: 2191–2202.
115.
MartelliAMEvangelistiCChiariniF, et al.The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients. Oncotarget2010; 1: 89–103.
116.
Sánchez-AlegríaKFlores-LeónMAvila-MuñozE, et al.PI3K Signaling in neurons: a central node for the control of multiple functions. Int J Mol Sci2018; 19: 3725.
117.
GuptaIGaykalovaDA. Unveiling the role of PIK3R1 in cancer: a comprehensive review of regulatory signaling and therapeutic implications. Semin Cancer Biol2024; 106–107: 58–86.
118.
MengDHeWZhangY, et al.Development of PI3K inhibitors: advances in clinical trials and new strategies. Pharmacol Res2021; 173: 105900.
119.
SadasivanCZhabyeyevPLabibD, et al.Cardiovascular toxicity of PI3Kα inhibitors. Clin Sci (Lond)2020; 134: 2595–2622.
120.
AdonTBhattacharyaSMadhunapantulaSV, et al.Structural requirements of isoform-specific inhibitors of Akt: implications in the development of effective cancer treatment strategies. Eur J Med Chem2025; 287: 117334.
121.
HassanDMengesCWTestaJR, et al.AKT Kinases as therapeutic targets. J Exp Clin Cancer Res2024; 43: 313.
122.
PervanidisKAD’AngeloGDWeisnerJ, et al.Akt inhibitor advancements: from capivasertib approval to covalent-allosteric promises. J Med Chem2024; 67: 6052–6063.
123.
KhezriMRMohammadipanahSGhasemnejad-BerenjiM. The pharmacological effects of berberine and its therapeutic potential in different diseases: role of the phosphatidylinositol 3-kinase/Akt signaling pathway. Phytother Res2024; 38: 349–367.
124.
WangJAnZWuZ, et al.Spatial organization of PI3K–PI(3,4,5)P3–AKT signaling by focal adhesions. Mol Cell2024; 84: 4401–4418.e4409.
125.
Marques-RamosACervantesR. Expression of mTOR in normal and pathological conditions. Mol Cancer2023; 22: 112.
126.
MichailidouDGartshteynYAskanaseAD, et al.The role of mTOR signaling pathway in systemic lupus erythematosus and systemic vasculitis. Autoimmun Rev2025; 24: 103910.
127.
IskandarKFooJLiewAQX, et al.A novel MTORC2–AKT–ROS axis triggers mitofission and mitophagy-associated execution of colorectal cancer cells upon drug-induced activation of mutant KRAS. Autophagy2024; 20: 1418–1441.
128.
Linde-GarelliKYRogalaKB. Structural mechanisms of the mTOR pathway. Curr Opin Struct Biol2023; 82: 102663.
129.
MaLPangZZhangH, et al.Clear cell renal carcinoma essentially requires CDKL3 for oncogenesis. Proc Natl Acad Sci U S A2025; 122: e2415244122.
130.
YangCZWangSHZhangRH, et al.Neuroprotective effect of astragalin via activating PI3K/Akt–mTOR-mediated autophagy on APP/PS1 mice. Cell Death Discov2023; 9: 15.
131.
LiMMoYYuQ, et al.Rotating magnetic field improves cognitive and memory impairments in APP/PS1 mice by activating autophagy and inhibiting the PI3K/AKT/mTOR signaling pathway. Exp Neurol2025; 383: 115029.
132.
WangQWangYLiS, et al.PACAP-Sirtuin3 alleviates cognitive impairment through autophagy in Alzheimer’s disease. Alzheimers Res Ther2023; 15: 184.
133.
QiWYingYWuP, et al.Inhibition of miR-4763-3p expression activates the PI3K/mTOR/Bcl2 autophagy signaling pathway to ameliorate cognitive decline. Int J Biol Sci2024; 20: 5999–6017.
134.
HindamMOAhmedLAEl SayedNS, et al.Repositioning of baricitinib for management of memory impairment in ovariectomized/D-galactose treated rats: a potential role of JAK2/STAT3–PI3K/AKT/mTOR signaling pathway. Life Sci2024; 351: 122838.
135.
WangYChenFWangP, et al.Study on myelin injury of AD mice treated with Shenzhiling oral liquid in the PI3K/Akt–mTOR pathway. Int J Immunopathol Pharmacol2020; 34: 2058738420923907.
136.
WangHLiQSunS, et al.Neuroprotective effects of salidroside in a mouse model of Alzheimer’s disease. Cell Mol Neurobiol2020; 40: 1133–1142.
137.
AnHJangYChoiJ, et al.New insights into AMPK, as a potential therapeutic target in metabolic dysfunction-associated steatotic liver disease and hepatic fibrosis. Biomol Ther (Seoul)2025; 33: 18–38.
138.
NajafovALuuHSMookhtiarAK, et al.RIPK1 Promotes energy sensing by the mTORC1 pathway. Mol Cell2021; 81: 370–385.e377.
139.
TangWQLiuYJiCH, et al.Virus-mediated decrease of LKB1 activity in the mPFC diminishes stress-induced depressive-like behaviors in mice. Biochem Pharmacol2022; 197: 114885.
140.
ZhangJGongHZhaoT, et al.AMPK-upregulated microRNA-708 plays as a suppressor of cellular senescence and aging via downregulating disabled-2 and mTORC1 activation. MedComm(2020) 2024; 5: e475.
141.
LiRHeTYangM, et al.Regulation of Bacillus Calmette–Guérin-induced macrophage autophagy and apoptosis by the AMPK–mTOR–ULK1 pathway. Microbiol Res2025; 290: 127952.
142.
ShaoBBuHLiG, et al.Autophagy-dependent apoptosis induction by oridonin is mediated by ROS-dependent AMPK–mTOR–ULK1 pathway in colon cancer. Am J Cancer Res2025; 15: 1902–1918.
143.
FaikogluGSaygisever-FaikogluKOzbasakH, et al.Neuroprotective effects of phosphodiesterase inhibitors on sestrin-2 (SESN2) expression and autophagy in Alzheimer’s disease model. Cureus2025; 17: e88449.
144.
LiuJZhangYZhangM, et al.6‴-Feruloylspinosin Alleviates Aβ-induced toxicity by modulating relevant neurotransmitter and the AMPK/mTOR signaling pathway. Free Radic Biol Med2025; 227: 434–445.
145.
ZhaoWYangRMengX, et al.Panax quinquefolium saponins protect neuronal activity by promoting mitophagy in models of Alzheimer’s disease. J Ethnopharmacol2025; 340: 119250.
146.
ChengXDaiYShangB, et al.Danggui Shaoyao San and disassembled prescription: neuroprotective effects via AMPK/mTOR-mediated autophagy in mice. BMC Complement Med Ther2024; 24: 298.
147.
Abdel-LahESSherkawyHSMohamedWH, et al.Empagliflozin and memantine combination ameliorates cognitive impairment in scopolamine + heavy metal mixture-induced Alzheimer's disease in rats: role of AMPK/mTOR, BDNF, BACE-1, neuroinflammation, and oxidative stress. Inflammopharmacology2025; 33: 3479–3498.
148.
NongWChenXChenY, et al.Natural polyphenol mangiferin delays neuronal cell senescence by inhibiting neuroinflammation mediated by microglial activation. IBRO Neurosci Rep2025; 18: 574–591.
149.
WangXJiaJ. Magnolol improves Alzheimer’s disease-like pathologies and cognitive decline by promoting autophagy through activation of the AMPK/mTOR/ULK1 pathway. Biomed Pharmacother2023; 161: 114473.
150.
CrullEBJainANHawkinsPCD, et al.Unmasking the true identity of rapamycin’s minor conformer. J Nat Prod2023; 86: 1862–1869.
151.
FriasMAHatipogluAFosterDA. Regulation of mTOR by phosphatidic acid. Trends Endocrinol Metab2023; 34: 170–180.
152.
OleksakPNepovimovaEChrienovaZ, et al.Contemporary mTOR inhibitor scaffolds to diseases breakdown: a patent review (2015–2021). Eur J Med Chem2022; 238: 114498.
153.
GonzalesMMGarbarinoVRKautzTF, et al.Rapamycin treatment for Alzheimer’s disease and related dementias: a pilot phase 1 clinical trial. Commun Med (Lond)2025; 5: 189.
154.
LiMZLiuEJZhouQZ, et al.Intracellular accumulation of tau inhibits autophagosome formation by activating TIA1-amino acid-mTORC1 signaling. Mil Med Res2022; 9: 38.
155.
GuoWZhongWHaoL, et al.Activation of mTORC1 by free fatty acids suppresses LAMP2 and autophagy function via ER stress in alcohol-related liver disease. Cells2021; 10: 2730.
156.
ParkHSSongJWParkJH, et al.TXNIP/VDUP1 attenuates steatohepatitis via autophagy and fatty acid oxidation. Autophagy2021; 17: 2549–2564.
157.
CarosiJMSargeantTJ. Rapamycin and Alzheimer disease: a hypothesis for the effective use of rapamycin for treatment of neurodegenerative disease. Autophagy2023; 19: 2386–2390.
158.
De PascaleMBisseggerLTarantelliC, et al.Investigation of morpholine isosters for a potent, selective and metabolically stable mTOR kinase inhibitor. Eur J Med Chem2023; 248: 115038.
159.
BinkhathlanZAlshememryAKBalkhairAM, et al.Development, characterization, and in vitro evaluation of poly(ethylene oxide)-block-poly(ɛ-caprolactone)-α-tocopheryl succinate micelles as a novel nanocarrier for rapamycin delivery. Int J Pharm X2025; 9: 100341.
160.
BurkeJAZhangXBobbalaS, et al.Subcutaneous nanotherapy repurposes the immunosuppressive mechanism of rapamycin to enhance allogeneic islet graft viability. Nat Nanotechnol2022; 17: 319–330.
161.
CraparoEFDragoSEQuagliaF, et al.Novel rapamycin-loaded nano- into micro-formulation for treatment of lung inflammation. Drug Deliv Transl Res2022; 12: 1859–1872.
162.
ShiGChiramelAILiT, et al.Rapalogs downmodulate intrinsic immunity and promote cell entry of SARS-CoV-2. J Clin Invest2022; 132: e160766.
163.
TasianSKSilvermanLBWhitlockJA, et al.Temsirolimus combined with cyclophosphamide and etoposide for pediatric patients with relapsed/refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium trial (TACL 2014-001). Haematologica2022; 107: 2295–2303.
164.
DuHYangYCLiuHJ, et al.Bi-steric mTORC1 inhibitors induce apoptotic cell death in tumor models with hyperactivated mTORC1. J Clin Invest2023; 133: e167861.
165.
Jhanwar-UniyalMZellerSLSpirollariE, et al.Discrete mechanistic target of rapamycin signaling pathways, stem cells, and therapeutic targets. Cells2024; 13: 409.
166.
TheilmannWGerickeBSchidlitzkiA, et al.Novel brain permeant mTORC1/2 inhibitors are as efficacious as rapamycin or everolimus in mouse models of acquired partial epilepsy and tuberous sclerosis complex. Neuropharmacology2020; 180: 108297.
167.
CassanoTMaginiAGiovagnoliS, et al.Early intrathecal infusion of everolimus restores cognitive function and mood in a murine model of Alzheimer’s disease. Exp Neurol2019; 311: 88–105.
168.
LiFChenYZhengW, et al.Everolimus alleviates cognitive dysfunction in 5×FAD mice by regulating mitochondrial function and oxidative stress. Eur J Pharmacol2025; 1003: 177974.
169.
JiangTYuJTZhuXC, et al.Temsirolimus promotes autophagic clearance of amyloid-β and provides protective effects in models of Alzheimer’s disease. Pharmacol Res2014; 81: 54–63.
170.
JiangTYuJTZhuXC, et al.Temsirolimus attenuates tauopathy by targeting tau hyperphosphorylation and autophagic clearance. Neuropharmacology2014; 85: 121–130.
171.
AliESMitraKAkterS, et al.Recent advances and limitations of mTOR inhibitors in the treatment of cancer. Cancer Cell Int2022; 22: 284.
172.
ChenYZhouX. Research progress of mTOR inhibitors. Eur J Med Chem2020; 208: 112820.
173.
MaoBZhangQMaL, et al.Overview of research into mTOR inhibitors. Molecules2022; 27: 5295.
174.
ZhangZFanQLuoX, et al.Brain-restricted mTOR inhibition with binary pharmacology. Nature2022; 609: 822–828.
175.
ChongCMTanYTongJ, et al.Presenilin-1 F105C mutation leads to tau accumulation via the Akt/mTORC1 signaling pathway. Cell Biosci2022; 12: 131.
176.
HaageVTuddenhamJFComandante-LouN, et al.A pharmacological toolkit for human microglia identifies Topoisomerase I inhibitors as immunomodulators for Alzheimer’s disease. bioRxiv2024. doi: 10.1101/2024.02.06.579103
177.
SalamaMElhussinyMMagdyA, et al.Dual mTORC1/mTORC2 blocker as a possible therapy for tauopathy in a cellular model. Metab Brain Dis2019; 33: 583–587.
178.
WangYTortorellaM. Molecular design of dual inhibitors of PI3K and potential molecular target of cancer for its treatment: a review. Eur J Med Chem2022; 228: 114039.
179.
YangCChenYWuT, et al.Discovery of FD274 as a highly potent PI3K/mTOR dual inhibitor for AML. Eur J Med Chem2023; 258: 115543.
180.
ZhengTSunCYunC, et al.Unlocking the therapeutic potential of DNA-PKcs in cancer: comprehensive insights into mechanisms and clinical applications. Cancers (Basel)2025; 17: 2787.
181.
MiaoXLiuCJiangY, et al.BET Protein inhibition enhances sensitivity to PI3K/mTOR dual inhibition in intrahepatic cholangiocarcinoma. Cell Death Dis2021; 12: 1020.
182.
SunCYLiYZCaoD, et al.Rapamycin and trametinib: a rational combination for treatment of NSCLC. Int J Biol Sci2021; 17: 3211–3223.
183.
TanLZhangJWangY, et al.Development of dual inhibitors targeting epidermal growth factor receptor in cancer therapy. J Med Chem2022; 65: 5149–5183.
184.
BelloziPMQGomesGFde OliveiraLR, et al.NVP-BEZ235 (dactolisib) has protective effects in a transgenic mouse model of Alzheimer’s disease. Front Pharmacol2019; 10: 1345.
185.
Rodrik-OutmezguineVSOkaniwaMYaoZ, et al.Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor. Nature2016; 534: 272–276.
186.
YangGFrancisDKrycerJR, et al.Dissecting the biology of mTORC1 beyond rapamycin. Sci Signal2021; 14: eabe0161.
187.
HartungHPCreeBACBarnettM, et al.Bioavailable CNS disease-modifying therapies for multiple sclerosis. Front Immunol2023; 14: 1290666.
188.
ChakrabortySAhlerESimonJJ, et al.Profiling of drug resistance in Src kinase at scale uncovers a regulatory network coupling autoinhibition and catalytic domain dynamics. Cell Chem Biol2024; 31: 207–220.e11.
189.
SavillKMZLeeBBOehJ, et al.Distinct resistance mechanisms arise to allosteric vs ATP-competitive AKT inhibitors. Nat Commun2022; 13: 2057.
190.
WangYYYanQHuangZT, et al.Ameliorating ribosylation-induced amyloid-β pathology by berberine via inhibiting mTOR/p70S6K signaling. J Alzheimers Dis2021; 79: 833–844.
191.
ChenXTianQGaoM, et al.Lingguizhugan decoction enhances autophagy of Alzheimer’s disease via regulating the mTOR/p70S6K pathway in vivo and in vitro. Front Aging Neurosci2025; 17: 1478199.
192.
ZhengXLinWJiangY, et al.Electroacupuncture ameliorates β-amyloid pathology and cognitive impairment via activation of TFEB. Autophagy2021; 17: 3833–3847.
193.
ZhengXLuoZZhengJ, et al.Electroacupuncture attenuates high-fat diet–exacerbated Alzheimer’s pathology by enhancing TFEB/TFE3-mediated autophagic clearance of tau and NLRP3 inflammasome in 3xTg mice. CNS Neurosci Ther2025; 31: e70497.
194.
ZhangYFXiongWNMaYY, et al.Exploring the mechanism of action of acupuncture for Alzheimer’s disease based on the immune-metabolic network perspective. Integr Med Discov2025; 9: e25014.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
